The acquisition will help the company to better serve its customers across both human and animal health market segments. Overall investment in the US facility is estimated at around USD 50 million, including the cost of acquisition (USD 36.5 million) and expenses to make the facility operational. The acquisition is expected to close in March 2025, subject to the satisfaction of customary closing conditions, it said. Syngene International shares on Monday ended 0.22 per cent down at Rs 678 apiece on BSE. The company has acquired the site from Emergent Manufacturing Operations Baltimore, LLC, for around $50 million, the company said in a statement. It is a wholly-owned subsidiary of the company, and will be based in Baltimore, Maryland, it added. The deal was announced at the annual meeting of the American Association of Manufacturers (AAM) in Washington, D.C. on Monday. The AAM is the world’s largest maker of animal health products and supplies. It has more than 100,000 employees across the U.S., Canada, Australia, New Zealand and the UK.